Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified liposarcoma.
Mark Andrew Dickson
Consultant or Advisory Role - Pfizer
William D. Tap
No relevant relationships to disclose
Mary Louise Keohan
No relevant relationships to disclose
Sandra P. D'Angelo
No relevant relationships to disclose
Mrinal M. Gounder
No relevant relationships to disclose
Ping Chi
No relevant relationships to disclose
Cristina R. Antonescu
No relevant relationships to disclose
Jonathan Landa
No relevant relationships to disclose
Li-Xuan Qin
No relevant relationships to disclose
Dustin D. Rathbone
No relevant relationships to disclose
Yelena Ustoyev
No relevant relationships to disclose
Aimee Marie Crago
No relevant relationships to disclose
Samuel Singer
Consultant or Advisory Role - Pfizer
Gary K. Schwartz
Consultant or Advisory Role - Pfizer
Mercedes M. Condy
No relevant relationships to disclose